Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

Biontech Ag

Dana-farber-cancer Institute Inc.

The Broad Institute, Inc.

Bayer Healthcare LLC

Dieter Moosmayer

Knut Eis

Uwe Eberspächer

Philip Lienau

Gerhard Siemeister

Hans Briem

Ulrich Lücking

Hans Schick

Benjamin Bader

Antje Margret Wengner

Marcus Koppitz

Wilhelm Bone

Lars Wortmann

Klaus Pfizenmaier

Ulrich Klar

Ulf Bömer

Klemens Lustig

Markus Berger

Matthew Meyerson

Martina Schäfer

Heinrich Meier

Niels Lindner

Detlev Sülzle

Volker Schulze

Ursula Mönning

Tobias Marquardt

Dmitry Zubov

Thomas Neubauer

Kirstin Petersen

Keith Graham

Zhuozhi Wang

Julien Lefranc

Joanna Grudzinska-Goebel

Franz Von Nussbaum

Harald Wajant

Thomas Wuest

Heidi Greulich

Stephan Siegel

Carsten Terjung

Kersten Matthias Gericke

Damian Brockschnieder

Franziska Siegel

Daniel Korr

Florian Kölling

Volker Badock

Nicole Biber

Bethany Kaplan

Hideki Miyatake Ondozabal

Jörg Meding

Hassan Youssef Harb

Andreas Timmermann

Stephen Moore

Alexander Schulz

Phi Manh Dinh

Thomas Wüest

John Murphy

Antje-Margret Wengner

Eis Knut

Hans (deceased) Schick

Uwe Eberspacher

Ulrich Lucking

The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.

2-(morpholin-4-yl)-1,7-naphthyridines

Compounds of formula (I) processes for their production and their use as pharmaceuticals. 

4H-pyrrolo[3,2-c]pyridin-4-one derivatives

The present application relates to novel substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones of formula (I), to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of lung inflammation disorders. 

Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-C][1,2,4]triazol-3-ones, and use thereof

The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (1b), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients. 

Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumour tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimised for the respective indication/tumour entity.

Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZe (antibody-mediated apoptosis inducing cytokines)

Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumor tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimized for the respective indication/tumor entity.

Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZEe (antibody-mediated apoptosis inducing cytokines)

Growing community of inventors

Berlin, Germany

Dieter Moosmayer